Literature DB >> 29851119

Annotated guidance to the European Medicines Agency (EMA) guidelines and regulatory documents. A new series of the BJCP.

Adam Cohen1, Sergio Bonini2.   

Abstract

Mesh:

Year:  2018        PMID: 29851119      PMCID: PMC6005623          DOI: 10.1111/bcp.13599

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  4 in total

1.  Annotated guidance to the European Medicines Agency (EMA) guidelines and regulatory documents. A new series of the BJCP.

Authors:  Adam Cohen; Sergio Bonini
Journal:  Br J Clin Pharmacol       Date:  2018-05-30       Impact factor: 4.335

2.  Commentary on the EMA Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products.

Authors:  Joop van Gerven; Milton Bonelli
Journal:  Br J Clin Pharmacol       Date:  2018-05-30       Impact factor: 4.335

3.  Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase.

Authors:  Anne Kerbrat; Jean-Christophe Ferré; Pierre Fillatre; Thomas Ronzière; Stéphane Vannier; Béatrice Carsin-Nicol; Sylvain Lavoué; Marc Vérin; Jean-Yves Gauvrit; Yves Le Tulzo; Gilles Edan
Journal:  N Engl J Med       Date:  2016-11-03       Impact factor: 91.245

4.  Implications of the BIA-102474-101 study for review of first-into-human clinical trials.

Authors:  Michael Eddleston; Adam F Cohen; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2016-04       Impact factor: 4.335

  4 in total
  5 in total

1.  Regulatory science: Regulation is too important to leave it to the regulators.

Authors:  Hubert G Leufkens
Journal:  Br J Clin Pharmacol       Date:  2019-04-10       Impact factor: 4.335

2.  Annotated guidance to the European Medicines Agency (EMA) guidelines and regulatory documents. A new series of the BJCP.

Authors:  Adam Cohen; Sergio Bonini
Journal:  Br J Clin Pharmacol       Date:  2018-05-30       Impact factor: 4.335

Review 3.  Regulatory aspects of the development of drugs for metabolic bone diseases - FDA and EMA perspective.

Authors:  Theresa Kehoe; Eberhard Blind; Heidi Janssen
Journal:  Br J Clin Pharmacol       Date:  2018-12-03       Impact factor: 4.335

Review 4.  Pharmacometrics and systems pharmacology for metabolic bone diseases.

Authors:  Matthew M Riggs; Serge Cremers
Journal:  Br J Clin Pharmacol       Date:  2019-02-28       Impact factor: 4.335

5.  Nulelìntàm èli Paèkw.

Authors:  Serge Cremers
Journal:  Br J Clin Pharmacol       Date:  2020-01-07       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.